Renovaro Biosciences Announces Results of Special Meeting of Shareholders
25 Enero 2024 - 11:45AM
Renovaro Biosciences Announces Results of Special Meeting of
Shareholders
Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a
biotechnology corporation focusing on cell, gene, and
immunotherapy, announced today the results of the Company’s Special
Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.
All of the matters put forward before the Company's shareholders
for consideration and approval, as set out in the Company's
definitive proxy statement dated January 3, 2024, were
approved by the requisite number of votes cast at the meeting.
For complete results on all matters voted on at the meeting,
please consult the Company's Form 8-K which will be filed on EDGAR
at www.sec.gov/edgar.
ABOUT THE COMPANYRenovaro has developed
advanced cell, gene, and immunotherapy platforms designed to renew
the body’s natural tumor-fighting capabilities against cancer and
infectious diseases. For more information on Renovaro, go to their
website at www.renovarobio.com.
Contact: ir@renovarobio.comSource: Renovaro
Bioscience Inc.
Renovaro (TG:2Q5)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Renovaro (TG:2Q5)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024